May 23, 2020 – The Philippines has approved clinical trials for a potential coronavirus disease (COVID-19) vaccines, joining tests with China and Taiwan, according to the government’s inter-agency task force on addressing the pandemic.
The country has earlier approved two clinical trials to find a cure for the highly contagious respiratory disease – a global solidarity trial for a combination of drugs and a Japanese anti-viral drug Avigan.
In his 8th report to Congress on May 18, President Rodrigo Duterte said the Department of Science and Technology (DOST) had raised the possibility of collaborating with the two foreign-based research groups.
The Philippines will be will be working closely with the Adimmune Corporation and Academia Sinica of Taiwan, as well as the Guangzhou Institute of Biomedicine and Health-Chinese Academy of Science, and SinoPharm (Wuhan Institute of Biological Products and Beijing Institute).
Reuters reported China has two potential vaccines under clinical trials — one of which is an inactivated vaccine, according to Chinese Center for Disease Control and Prevention director Gao Fu.
It has entered the second phase of clinical trials on Friday. The potential vaccine was developed by the Wuhan Institute of Biological Products, under the China National Pharmaceutical Group (Sinopharm) and the Wuhan Institute of Virology under the Chinese Academy of Sciences.
The decision to join the clinical trials was reached after the DOST recommended to the inter-agency for the management of emerging infectious diseases in its last meeting.
The inter-agency task force has instructed the Food and Drug Administration (FDA) to facilitate the issuances of permits to conduct trials in the Philippines.
Once completed, the trials will be part of the requirements for the vaccine registration process by the FDA, and the issuance of the Certificate of Product Registration (CPR) for market release in the country according to the IATF.
Apart from these, the Philippines has joined other trials for anti-COVID drugs.
In the president’s report, at least 24 hospitals are actively participating in the World Health Organization (WHO) Solidarity trials, with 12 of them actively recruiting participants. At least 87 people are enrolled in the trials.
The Department of Health (DOH) has also allocated 18-million pesos for the trials of the drug Avigan. The medication, commonly known as favipiravir, was previously used to treat influenza. There are three identified sites for the Avigan trials with a target of 80-100 test subjects.
The IATF said they also support plans to establish the Virology S&T Institute in New Clark City, and the reactivation of the Pharmaceutical Development Unit in DOST to initiate and strengthen local vaccine development.
(Katrina Elaine Alba/MM)
Our Privacy Commitment
TV5 Network Inc. values and respects your right to privacy. We are committed to safeguarding your personal data in compliance with Republic Act No. 10173 or the Data Privacy Act of 2012 and its Implementing Rules and Regulations.
Why do we collect your personal information (as applicable)?
We collect and maintain basic information about you as users of TV5 sites for the following purposes:
Where do we get your personal information?
There are several ways we collect your personal information.
Information that you personally provided.
Most of the personal information we have are those that you have provided us when you:
Information we collect during your engagement with us
We also collect information as you use our products and services, like:
Information we collect from other sources
We also collect your personal information through other activities such as our market research initiatives, when you visit and use our websites and mobile apps, and from our subsidiaries, affiliates, and third-party business partners to whom you have given consent to share your information to us.
When do we disclose personal information?
There are circumstances when we are required to share some of the information you have provided us. In these cases, we ensure that your personal information will be disclosed on a confidential manner, through secure channels that is in compliance with the Data Privacy Act and other privacy laws.
In some instances, we may be required to disclose your personal information to our agents, subsidiaries, affiliates, business partners and other third-party agencies and service providers as part of our regular business operations and for the provision of our programs and services. This means we might share your information with:
How we protect your personal information
We also put in effect the following safeguards:
TV5 will not collect, use, or disclose your personal information for any purpose other than those identified in this Commitment, your Service Agreement or our Terms of Service, and any other purpose that you may have given your consent for.
For greater clarity, unless you provide specific consent, we shall not:
What are your choices?
You are given certain rights in relation to your personal data under the Data Privacy Act. We would like to ensure that we have your consent to continue to collect, use, and disclose your personal information for the purposes that we have identified. We want you to know that you do have choices and can object or withdraw your consent and/or edit your consent preferences at any time.
If you wish to have access to your personal information in our records; or you think that such personal information we have of you is incomplete, not up-to-date, or otherwise inaccurate, you may get in touch with our Data Privacy Officer through the contact details provided below. In some instances, we may request for supporting documents or proof before we effect any requested changes to your personal information.
Data Protection Officer
TV5 Network Inc.
Reliance corner Sheridan Streets
What happens when there are changes in our Policy?
You will always be provided notice if these changes are significant and, if we are required by law, we will ensure to obtain your updated consent.